Trump signs order speeding review of psychedelic drugs, including ibogaine

<br><br>**Breaking News Trump Signs Order to Expedite Review of Psychedelic Drugs,<br>Drugs, Including Ibogaine**<br><br>In a surprising move, President Donald Trump has signed an executive order <br>directing his administration to expedite reviews of certain psychedelic dru<br>drugs, including ibogaine. The goal is to ease restrictions and spur resear<br>research on using these substances for medical purposes, such as treating s<br>severe depression.<br><br>**A Beacon of Hope for Combat Veterans and Conservative Lawmakers**<br><br>Ibogaine, a substance derived from a shrub native to West Africa, has gaine<br>gained popularity among combat veterans and conservative lawmakers for its <br>potential to treat post-traumatic stress disorder (PTSD) and opioid addicti<br>addiction. The drug's advocates claim it has great promise in helping indiv<br>individuals recover from traumatic experiences.<br><br>**A Complex History**<br><br>Ibogaine's history is marked by controversy and concern over its safety ris<br>risks. While it has been used in religious ceremonies in African nations, t<br>the drug has also been linked to more than 30 deaths in medical literature,<br>literature, according to the Multidisciplinary Association for Psychedelic <br>Studies (MAPS).<br><br>**The FDA Responds**<br><br>In response to Trump's order, the Food and Drug Administration (FDA) will i<br>issue national priority vouchers for three psychedelics, including ibogaine<br>ibogaine. This move will allow certain drugs to be approved quickly if they<br>they align with the agency's national priorities.<br><br>**Veterans' Advocacy Group Welcomes the Move**<br><br>Tom Feegel, owner of Beond Ibogaine, a clinic in Cancun, Mexico that treats<br>treats patients with ibogaine, welcomes the order. What it does mean is th<br>that ibogaine shifts from being fringe and underground to being federally a<br>acknowledged, he said.<br><br>**Research and Regulation**<br><br>The FDA's Commissioner, Marty Makary, emphasized the importance of conducti<br>conducting rigorous research on psychedelics. The agency will take steps to<br>to clear the way for human trials of ibogaine in the US. Frederick Barrett,<br>Barrett, director of the Johns Hopkins Center for Psychedelic and Conscious<br>Consciousness Research, praised the move, saying it would help researchers <br>understand whether ibogaine is truly a better psychedelic therapy.<br><br>**Conclusion**<br><br>Trump's executive order marks a significant shift in the landscape of psych<br>psychedelic drug research. While the path forward will be complicated by sa<br>safety concerns and regulatory hurdles, this move could pave the way for mo<br>more thorough study of these substances. As the debate continues, one thing<br>thing is clear ibogaine has become a lightning rod for discussion around p<br>psychedelics and their potential therapeutic applications.<br><br>**Keywords** psychedelic drugs, ibogaine, Trump, FDA, psychedelic research<br>research, PTSD, opioid addiction